OptiBiotix Health PLC Manufacturing, supply and profit sharing agreement (6240I)
12 Agosto 2019 - 01:00AM
UK Regulatory
TIDMOPTI
RNS Number : 6240I
OptiBiotix Health PLC
12 August 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Manufacturing, supply and profit sharing agreement with Maxum
Foods Pty Ltd.
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skin care, announces it has entered
into a manufacturing, supply and distribution agreement with Maxum
Foods Pty Ltd ("Maxum"). The agreement grants Maxum an exclusive
license to manufacture, supply and distribute OptiBiotix's
SlimBiome(R) weight management technology in Australia and New
Zealand.
Founded in 2003, Maxum is an Australia-based dairy supplier
headquartered in Brisbane and operating a dry blending facility in
Melbourne, as well as distribution centres throughout Australia and
New Zealand. Maxum has been named one of Australia's
fastest-growing SMEs on the 2018 Smart50 list with a turnover of
AUS$150.7 million in 2018 and a 110% growth between 2016 and
2018.
SlimBiome(R), an award winning weight management product, will
be supplied by Maxum as a specialised functional ingredient, into a
wide range of applications including, but not limited to, human
nutrition comprising food and beverages, dairy, dietary supplements
and sports nutrition.
This is another strategic step by OptiBiotix to derisk its
supply chain and extend the market reach of SlimBiome(R) by adding
manufacturing in Australia. Partnering with an established
distributor that services over 950 customers and to whom it sells
approximately 35,000 metric tonnes of dairy per year, will extend
the commercial opportunity for OptiBiotix's patented award winning
weight management product into the Australian weight management
market which is estimated to be worth AUS$320 million in 2019
(source: ibisworld.com.au).
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented: "We are pleased to announce the signing of a
manufacturing and supply agreement with Maxum. We chose Maxum due
to their knowledge of the Australian and New Zealand markets as
well as their experience in distributing specialty ingredients like
SlimBiome(R) and their reputation for supplying high-quality
products to the food industry. We believe working with Maxum, and
similar partners around the world, provides the best opportunity of
increasing our global commercial reach and catering to the growing
interest we are seeing in SlimBiome(R) from partners
worldwide."
Dustin Boughton, Director of Maxum stated: "We are excited to be
working with OptiBiotix in Australia and New Zealand. Our
logistical and technical expertise and access to distribution
channels within these markets means this is a natural fit for both
companies. The manufacturing and supply of SlimBiome(R) is aligned
with our goal of bringing innovative and high quality products to
our customers."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRKMGGRKLZGLZM
(END) Dow Jones Newswires
August 12, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024